Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Lu-OncoFAP-23 Alone or With L19-IL2 in Metastatic FAP-positive Solid Tumors
NCT06640413Phase 1Recruiting
- Sponsor
- Philogen
- Start
- Oct 2025
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lutetium lu 177 oncofap-23 in solid tumor (7 arms), sponsored by Philogen. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 5 more. Started Oct 2025; status: recruiting.
02
Drugs
lutetium lu 177 oncofap-23
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06640413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06640413.